The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective
Open accessAbstract
New blood vessels formation from the existing vasculature is called angiogenesis. It is an essential physiological process for the growth of cells, tissue repair, wound healing, and reproductive system of females. The process of angiogenesis regulation is related to diseases such as rheumatism arthritis, diabetes, atherosclerosis, and cancer. The growth and metastasis of the tumor is directly depend on the process of tumor angiogenesis. Tumor angiogenesis is regulated by the proangiogenic factors and anti-angiogenic factors formed by the host cells as well as the tumor cells. Among various growth factors, namely VEGFs, PDGFs, FGFs, and cytokines; VEGFs and its receptor VEGFR-2 (KDR) have a significant impact on the process of angiogenesis. After the activation initiated, KDR undergoes autophosphorylation that ultimately leads to a proliferation of the endothelial cells, tumor angiogenesis, tumor growth, and metastasis. VEGFR-2 overexpression is observed in different kinds of cancer, namely breast cancer, cervical cancer, non-small cell lung cancer, hepatocellular carcinoma, renal carcinoma, and likewise. Over the past decade, several VEGFR-2 inhibitors have been developed. Angiogenesis inhibition by blocking the VEGFR-2 is an emerging strategy to develop selective and specific anticancer agents. The review articles published before were based on the structure and biology of VEGFR-2 rather than medicinal chemistry. While the emphasis of the current review article is to summarise, the recent advancement regarding VEGFR-2 inhibitors concerning medicinal chemistry approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Singh, D. P., Pathak, R., Chintalaramulu, N., Pandit, A., Kumar, A., Ebenezer, P. J., Kumar, S., Duplooy, A., White, M. E., Jambunathan, N., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00821-4 · Cited by 12
Pro-Angiogenetic Effects of Purified Extracts from Helix aspersa during Zebrafish Development
Zizioli, D., Mastinu, A., Muscò, A., Bonini, S. A., Finazzi, D., Avisani, R., Kron Morelli, G. B., Pecorelli, S., & Memo, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44080232 · Cited by 4
Metadata
- Authors
- Modi, S. J., & Kulkarni, V. M.
- Venue
- Medicine in Drug Discovery
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 2
- Pages
- 100009
- ISSN
- 2590-0986 (ISSN-L)
- OpenAlex
- W2981810096
- Cited by
- 320
- References
- 152
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. https://app.cochat.ai/papers/10.1016/j.medidd.2019.100009
- The paper
- Modi, S. J., & Kulkarni, V. M. (2019). Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. Medicine in Drug Discovery. https://doi.org/10.1016/j.medidd.2019.100009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
